Status:
RECRUITING
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
Lead Sponsor:
Tongji Hospital
Conditions:
Nonalcoholic Fatty Liver Disease
Metabolic-associated Fatty Liver Disease
Eligibility:
All Genders
Brief Summary
The purpose of this study is to explore the value of new MR technology in assessing the systemic metabolism, disease status, and prognostic risk of metabolism-related fatty liver disease. By obtaining...
Detailed Description
Non-alcoholic fatty liver disease (NAFLD) is a chronic progressive liver disease caused by overnutrition and insulin resistance (IR) in genetically susceptible individuals. The disease spectrum includ...
Eligibility Criteria
Inclusion
- Patients with MR examination are clinically suspected or diagnosed with metabolism-related fatty liver disease;
- Age/gender: unlimited;
- Patients who voluntarily participate in clinical trials and sign written subject informed consent
Exclusion
- Clinical suspicion or diagnosis of metabolism-related fatty liver disease and having been prescribed an MR examination;
- Voluntarily participation in the study and provision of written informed consent.
Key Trial Info
Start Date :
April 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2032
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT07149571
Start Date
April 1 2025
End Date
December 31 2032
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji hospital
Wuhan, Hubei, China